What is Wedbush’s Forecast for Arvinas Q1 Earnings?

Arvinas, Inc. (NASDAQ:ARVN) – Equities research analysts at Wedbush issued their Q1 2026 earnings estimates for shares of Arvinas in a research note issued on Wednesday, November 5th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.63) for the quarter. Wedbush has a “Neutral” rating and a $9.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2026 earnings at ($0.65) EPS.

ARVN has been the subject of a number of other research reports. Barclays upped their target price on Arvinas from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Arvinas in a research report on Wednesday, October 8th. Bank of America lowered shares of Arvinas from a “buy” rating to a “neutral” rating and set a $10.00 price objective for the company. in a report on Wednesday, September 24th. Wells Fargo & Company cut their target price on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, HC Wainwright reduced their price target on shares of Arvinas from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $16.34.

Arvinas Price Performance

Shares of NASDAQ:ARVN opened at $10.63 on Friday. Arvinas has a 1 year low of $5.90 and a 1 year high of $28.70. The stock’s 50-day moving average is $8.83 and its 200 day moving average is $7.91. The company has a market cap of $682.66 million, a PE ratio of -13.12 and a beta of 2.38.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.27. The firm had revenue of $41.90 million during the quarter, compared to the consensus estimate of $29.36 million. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. The company’s quarterly revenue was down 59.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.68) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its holdings in shares of Arvinas by 965.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock valued at $33,000 after buying an additional 4,219 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after acquiring an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in Arvinas by 109.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares during the last quarter. CWM LLC boosted its stake in Arvinas by 2,317.5% during the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock valued at $53,000 after purchasing an additional 7,300 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Arvinas in the 3rd quarter worth $68,000. Institutional investors own 95.19% of the company’s stock.

Insider Transactions at Arvinas

In other news, Director Briggs Morrison acquired 30,000 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The shares were bought at an average cost of $7.57 per share, with a total value of $227,100.00. Following the transaction, the director owned 76,021 shares of the company’s stock, valued at $575,478.97. This trade represents a 65.19% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.73% of the stock is currently owned by insiders.

Arvinas declared that its board has authorized a stock buyback program on Wednesday, September 17th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the company to buy up to 17.9% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.